Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Bio-Rad Laboratories (BIO) stock in plain English

Free brief · no signupStart here
BIOPublished Nov 16, 2026
Bio-Rad Laboratories Inc
Healthcare · Medical Devices
Manufactures specialized instruments, software, and consumables used in life science research and clinical diagnostics.
Assets:
Droplet digital PCR baseThousands of proprietary genetic testing systems run in customer labs worldwide
Global manufacturing footprintFacilities operate across North America, Europe, and the Asia-Pacific region
8,000 employeesTechnical workforce serves research and hospital clients across more than 35 countries
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

77
OPS ScoreOperating finances
Latest quote
-0.72%$367.50
$9.93B
9.7×
$2.59B

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 16, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was BIO. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Bio-Rad Laboratories (BIO) do?

Bio-Rad Laboratories Inc (BIO) is a U.S.-listed company in Healthcare (Medical Devices). What it does: Manufactures specialized instruments, software, and consumables used in life science research and clinical diagnostics. It sells both life science research tools and clinical diagnostic test systems to laboratories worldwide. It is worth $9.93B on the market and sold $2.59B over the last year.

Market cap
$9.93B
P/E ratio
9.7×
Annual sales
$2.59B
Sector
Healthcare
Industry
Medical Devices
Brief updated
Nov 16, 2026

Brands and businesses behind BIO

  • Droplet Digital PCR: Testing equipment and consumables that measure absolute amounts of target DNA or RNA molecules without standard curves.
  • CFX Real-Time PCR: Laboratory thermal cyclers and optical detection systems that quantify specific gene sequences during clinical and academic research.
  • Bio-Plex: Multiplex testing instruments and assays that analyze dozens of cellular biomarkers simultaneously from a single patient sample.
  • D-10: Automated clinical analyzers that screen blood samples to measure hemoglobin levels for diabetes monitoring.
  • ChemiDoc: Digital imaging hardware and analysis software used to visualize proteins and nucleic acids in molecular biology labs.

BIO’s flags, in plain English

Each flag is a number from Bio-Rad Laboratories’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 16, 2026.

Insiders Hold

Insiders own 33.2% of the company. The people who run the company own a meaningful slice of it, so they gain or lose along with other shareholders.

Stupid Cash

Can pay this year's bills 3.2 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Low debt

Low debt, only 18% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.

Profit with Caveats

Bottom-line profit of $1.0B in the 12 months to Sep 30, 2026, next to a loss of $62M from the business itself. Bottom-line profit is well above what the business itself earned. The difference came from outside day-to-day operations, such as an investment gain, a tax benefit, the sale of a business or interest on its cash. Some of these may not repeat, and they make the P/E look lower than the business alone would.

2 more green flags and 2 more risk notes open with the free trial. Try it free for 7 days.

Questions about BIO

How big is Bio-Rad Laboratories?

Bio-Rad Laboratories’ market cap is $9.93B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $2.59B: what customers paid the company over the last year, before any costs.

What is BIO’s P/E ratio?

BIO’s P/E ratio is 9.7×. Investors pay about 9.7 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with BIO?

Reported earnings experience severe volatility because Bio-Rad must account for quarterly paper gains and losses from its minority stake in Sartorius AG. That is one risk on Bio-Rad Laboratories’ card. Its first risk flag is Profit with Caveats, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Bio-Rad Laboratories’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. BIO’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card